F110

Onkolytische Adenoviren
IDI:(DE-He78)F110-20160331

RTF

Recent Publications

All known publications ...
Download: BibTeX | EndNote XML,  Text | RIS | 

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.
Molecular therapy 3, 16018 - () [10.1038/mtm.2016.18]  GO DBCoverage   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;
Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation.
Journal of Immunology Research 2016, 1 - 17 () [10.1155/2016/6078473]  GO DBCoverage   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.
OncoTarget 7(8), 9046 - 9059 () [10.18632/oncotarget.7031]  GO pmc   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;
Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy
OncoImmunology 4(8), e1022302 - () [10.1080/2162402X.2015.1022302]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
OncoTarget 6(6), 4467 - 4481 () [10.18632/oncotarget.2901]  GO pmc   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;
Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
International journal of cancer 137(4), 978 - 990 () [10.1002/ijc.29442]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
International journal of cancer 136(9), 2228 - 2240 () [10.1002/ijc.29258]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
International journal of cancer 137(7), 1775 - 1783 () [10.1002/ijc.29536]  GO BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;
Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.
OncoTarget 5(15), 5893 - 5907 () [10.18632/oncotarget.1839]  GO pmc   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article  ;  ;  ;  ;  ;  ;  ;
Artificial riboswitches for gene expression and replication control of DNA and RNA viruses.
Proceedings of the National Academy of Sciences of the United States of America 111(5), E554 - E562 () [10.1073/pnas.1318563111]  GO pmc   Download fulltextFulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

All known publications ...
Download: BibTeX | EndNote XML,  Text | RIS | 


 Record created 2017-01-13, last modified 2022-03-18



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)